The adeno-associated virus (AAV) is the leading viral vector for in vivo gene therapy. Currently, production is labor intensive and expensive because of adherent cell culture processes. The use of stirred-tank bioreactors allows scalable and robust processes to be developed to meet the most demanding needs for high-dose indications that target large organs, e.g. muscle, skin, or blood. High-performing cell culture media is also crucial to ensure consistent supply.
Here, we highlight the development of two suspension-based AAV upstream production platforms and describe simplified cell culture processes to enable an efficient and cost-effective solution for large-scale AAV production.
In this webinar, you will learn about:
- Market insights, overall process considerations & trends for AAV
- High-performing suspension-based AAV upstream production platforms: VirusExpress® and Sf-RVN®
- Simplifying and optimizing your HEK-based suspension cell culture processes with the new Cellvento® 4HEK
Speakers
David Loong, Ph.D.
Merck
Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
David Loong is our senior consultant, novel modalities APAC, bioprocessing strategy. Previously, David held roles as a senior scientist in biotech startups encompassing cell & gene therapy process development services, mAb discovery, and preclinical development. He has an extensive track record providing contract research services as a senior research scientist at AMRI Global, and as a product custodian for API GMP manufacturing at GSK. He holds a Ph.D. in synthetic organic chemistry from the Australian National University and a BTech(Hons) from Massey University (NZ) specializing in chemistry and process engineering.
Rain Lee
Merck
Upstream Technical Application Expert, SEATW & Oceania
Rain is the USP technical application expert for SEATW & Oceania region in our company, based out of Singapore. She provides upstream technical application consultation and consideration for customers developing mAbs, vaccines, and cell and gene therapies.
Rain has more than 8 years of experience in the biopharmaceutical industry. She began her career as an R&D scientist. Prior to joining us, she worked in product management at ThermoFisher, supporting the life science industry. Driven by curiosity, she takes pride in providing the best possible solution and perspective in problem solving.
Pharma and biopharma manufacturing
- Viral Vector Upstream Processing
기간:1h
언어:English
세션 1:발표 완료 October 25, 2022
계속 읽으시려면 로그인하거나 계정을 생성하세요.
계정이 없으십니까?